


# CURRICULUM VITAE

Duha Mohammed Al-Shorafat, MD



## Contact Information

---

- Irbid-Jordan
- E-Mail: [Duha.AlShorafat@gmail.com](mailto:Duha.AlShorafat@gmail.com)

## Education/Certification

---

- 2020 Clinical fellowship in Movement disorders Surgical
- 2019 Clinical fellowship in Movement Disorders
- 2015 Jordanian Board of Neurology (Jordan Medical Council Certificate).
- 2015 Higher specialty certificate in Neurology (J.U.S.T)
- 2009 Medical Degree, Jordan University of Science & Technology (J.U.S.T.)

## Clinical Training

---

- **Jan 2020- Aug 2020** Clinical Fellowship in Movement Disorders Surgical, University Health Network/ University of Toronto
- **Jan 2018- Dec 2019** Clinical Fellowship in Movement Disorders, University Health Network/ University of Toronto.
- **Sep 2015- Dec 2017** Research and Teaching Assistant, Jordan University of Science and Technology (J.U.S.T).

- **Jul 2014- Jun 2015** Chief resident of Neurology, King Abdullah University Hospital (KAUH)/ J.U.S.T.
- **Jul 2010- Jun 2015** Neurology Residency, King Abdullah University Hospital (KAUH)/ J.U.S.T.
- **Jul 2009- Jun 2010** Internship, King Abdullah University Hospital (KAUH)/ J.U.S.T.
- **Sep 2003- Jun 2009** Medical School, Jordan University of Science and Technology J.U.S.T

### **Special Training/ Certificates**

---

- Principles and Practice of Clinical Research program. T.H Chan Public Health School. Harvard University. **March 2019-Nov 2019.**
- Cleveland Clinic 7<sup>th</sup> annual Neurotoxin Course for Neurological Conditions. Webinar series and full day live program. **October/November.2018**
- Standardized neurological examination and assessment of Kurtzke's Functional Systems and Expanded Disability Status Scale in Multiple Sclerosis Qualification (level C). **2014**
- National Institutes of Health Stroke Scale assessment- English Group A V3 in stroke patients Qualification. **2014**
- Diploma of French Language Studies (DELF). **2002**

## Memberships

---

- College of Physicians and Surgeons of Ontario. **Jan 2018-Aug 2020**
- American Academy of Neurology. **Active**
- International Parkinson and movement disorder society. **Active**

## Selected Conferences

---

- International Congress of Movement Disorders Society. Virtual Congress. **12<sup>th</sup> Sep 2020-16<sup>th</sup> Sep 2020**
- A Comprehensive Review of Movement Disorders for the Clinical Practitioner Aspen, CO, USA. **August 4-August 8,2020**
- International Congress of Movement Disorders Society. Nice, France. **22nd-26th September 2019.**
- American Academy of Neurology annual meeting. Philadelphia, USA. **May 2019**
- A Comprehensive Review of Movement Disorders for the Clinical Practitioner Aspen, CO, USA. **July9-August 2,2018**
- The 6<sup>th</sup> International Congress of the Jordanian Neurological Society; The 3rd congress of the Jordanian chapter of Epilepsy, Amman,Jordan. **October 21 -24 ,2015**
- The First Jordanian-Australian Neurosurgical Conference, King Abdullah University Hospital, Jordan. **April 27<sup>th</sup>, 2014.**
- The 5<sup>th</sup> International Congress of the Jordanian Neurological Society, Amman, Jordan. **November 8<sup>th</sup> -10<sup>th</sup>, 2012.**
- The First Scientific Day of The Department of Internal Medicine/ Faculty of Medicine. **April 3<sup>rd</sup>, 2007.**

## Teaching Experiences

---

- Movement disorders didactic course for neurology residents. **2015.**
- Neuroscience course for fifth year medical students. **2013-2017.**
- Introductory course for fourth year medical students. **2012-2017.**
- Neurosciences I, II course for third year medical students. **2012-2017.**

## Honors

---

- **2015** Best performance resident among all residency years.
- **2015** Top written Jordanian Board exam score among all examinees.
- **2015** Chief resident and resident representative in the department of neurology, Jordan University of Science and Technology.

## Selected Research / Clinical Trials

---

- Sub-Investigator in A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Trial to Evaluate the Efficacy and Safety of a Single Treatment of DaxibotulinumtoxinA for Injection in Adults with Isolated Cervical Dystonia (ASPEN-1) **2019.**
- Sub-Investigator in an open label Phase 2a Study to evaluate the Safety and tolerability of Perampanel (E2007) in subjects with Cervical Dystonia. **2018-2019.**
- Sub-Investigator in the Dystonia Coalition Project 1: Natural History and Biospecimen Repository for Dystonia. **2018- 2019.**
- Sub-Investigator in phase 3 FORT Study evaluating the safety and efficacy of fosmetpantotenate compared to placebo in patients with pantothenate kinase-associated neurodegeneration (PKAN). **2018- 2019**

- Sub-Investigator in a randomized placebo-controlled, 2-arm parallel-group superiority phase II study of Glycopyrrolate for moderate-to-severe sialorrhea in Parkinson's disease. **January-April, 2018.**
- Virtual Reality Based Motor Control Learning for people with Multiple Sclerosis: A pilot study. **2016-2017**
- Co-investigator in a single arm, open-label, multicenter study evaluating the long- term safety, tolerability and efficacy of 0.5 mg fingolimod. **2014-2016.**
- Cross-Cultural adaptation of the language/cognitive items of the NIHSS to the Arabic language validation study. **2014.**

## Publications/ Abstracts

---

### ❖ Publications:

- Mestre TA, Freitas E, Basndwah A, Lopez MR, de Oliveira LM, **Al-Shorafat DM**, Zhang T, Lui JP, Grimes D, Fox SH. Glycopyrrolate Improves Disability from Sialorrhea in Parkinson's Disease: A 12-Week Controlled Trial. *Mov Disord.* **2020 Jul 13.**
- **Al-Shorafat DM**, Lang AE. Amantadine for Gait Dysfunction in Pantothenate Kinase-Associated Neurodegeneration. *Can J Neurol Sci.* **2019 Aug 1:1-3.**
- Karlo J Lizarraga, **Duha Al-Shorafat**, and Susan Fox. Update on current and emerging therapies for dystonia. *Neurodegenerative Disease Management.* **2019 9:3, 135-147**
- Khalil H, Al-Sharman A, El-Salem K, Alghwiri AA, **Al-Shorafat D**, Khazaaleh S, Abu Foul L. The development and pilot evaluation of virtual reality balance scenarios in people with multiple sclerosis (MS): A feasibility study. *NeuroRehabilitation.* **2018;43(4):473-482.**
- Shadi Hamouri, **Duha Al-Shorafat**. Bilateral Facial Nerve Paralysis as first presentation of lung cancer. *Case Reports in Oncology, Karger* **2016;9:792-795. November,2016.**

- El-Salem K, Yassin A, Al-Hayk K. Yahya S, **Al-Shorafat D**, Dahbour S.S. Treatment of MuSK associated myasthenia gravis. Curr Treat Options Neurol. 2014 Apr; 16(4):28

- ❖ Accepted Abstracts

- **D. Al-Shorafat**, A. Shetty, D. Munoz, A. Fasano, A. Lang. Spectrum of parkinsonian phenotypes associated with GCH1 mutation. MDS congress 2019. Nice, France.
- H. Khalil, A. Al-Sharman, N. Alissa, K. El-Salem, **D. Al-Shorafat**. The association between pain and physical activity in people with Parkinson's Disease (PD). MDS congress 2018.
- Alham Al-Sharman, Hanan Khalil, Khalid El-Salem, **Duha Al-Shorafat**, Shada Khazaaleh, Lamis Abu alfoul. Understanding Motor Learning in Individuals with Multiple Sclerosis: Using Real-Life Task through Virtual Reality. ACSM- USA, 2018
- Hanan Khalil, Alham Al-Sharman, Khalid El-Salem, **Duha Al-Shorafat**, Patrick Esser, Helen Dawes. The extent of the Relationship between Sleep Disturbances and walking ability in people with Multiple Sclerosis. ACSM-USA, 2018
- Hanan Khalil, Alham Al-Sharman, Alia A. Alghwiri, Shada Kazaaleh, Lamees Abu foul, **Duha Al-Shorafat**, Khalid El-Salem. The Development and Evaluation of Virtual Reality Balance Scenarios in People with Multiple Sclerosis (MS): A pilot Study. Presented at the World Congress of Physical Therapy, 2017: Cape town, South Africa.

## Licenses

---

- College of Physicians and surgeons of Ontario. **Jan 2018-Aug 2020**
- Jordanian Medical License. **Active**
- Jordanian Neurology License. **Active**

## References

---

1. Susan H. Fox, MRCP (UK), PHD. Professor of Neurology, Movement Disorders Clinic. Associate director of the Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Center. 399 Bathurst St. Toronto, Ontario. M5T 2S8 Canada. E mail: [sfox@uhnresearch.ca](mailto:sfox@uhnresearch.ca). +1 416 603 6422.
2. Anthony E. Lang. MD, FRCPC. Professor of Neurology, Movement Disorders Clinic. Director of the Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Center. 399 Bathurst St. Toronto, Ontario. M5T 2S8 Canada. E mail: [Anthony.Lang@uhnresearch.ca](mailto:Anthony.Lang@uhnresearch.ca). +1 416 603 6422.
3. Alfonso Fasano. MD. PHD. Professor of Neurology, Movement Disorders Clinic. Co-Director of the surgical program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Center. 399 Bathurst St. Toronto, Ontario. M5T 2S8 Canada. E-mail: [alfonso.fasano@uhn.ca](mailto:alfonso.fasano@uhn.ca). +1 416 603 6422.